|Bid||0.4300 x 1300|
|Ask||0.4255 x 1000|
|Day's range||0.4200 - 0.4416|
|52-week range||0.4000 - 2.8100|
|Beta (5Y monthly)||1.05|
|PE ratio (TTM)||N/A|
|Earnings date||13 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.17|
IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -0.54%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Prostate Revenue Increased Year-Over-Year for Second Consecutive QuarterNon-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2022 ended September 30, 2021. Revenue for the first quarter of fiscal 2022 grew 8% to $
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.